A case report of a patient carrying CYP2C93/4 genotype with extremely low warfarin dose requirement

We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of ant...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2007, 22(3), , pp.557-559
Main Authors: Lee, Soo Youn, Nam, Myung Hyun, Kim, June Soo, Kim, Jong Won
Format: Article
Language:English
Subjects:
Aged
Anticoagulants - pharmacology
Aryl Hydrocarbon Hydroxylases - genetics
Atrial Fibrillation - drug therapy
Atrial Fibrillation - genetics
Case Report
Cytochrome P-450 CYP2C9
Female
Genotype
Heterozygote
Humans
International Normalized Ratio
Pharmacogenetics
Polymorphism, Genetic
Prothrombin Time
Warfarin - pharmacology
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.
ISSN:1011-8934
1598-6357
DOI:10.3346/jkms.2007.22.3.557